Senate Democrats are poised to pass a reconciliation bill next week that would, among other things, allow the federal government to "negotiate" prescription drug prices and more.
Sally C. Pipes, president and CEO of the Pacific Research Institute, spoke on the bill's impact and how it will affect inflation and the future of drug development. Sally has recently published op-eds on how the reconciliation package will undermine drug research in the likes of the Washington Examiner, Newsmax, and the Pittsburgh Post-Gazette. Find her article here.
HR 3 Rush To Reason March 12 2021 by John Rush
HR 1 Rush To Reason January 5 2021 by John Rush
HR 3 Rush To Reason May 6 2021 by John Rush